Contamination at drug plant could affect global supplies of bladder cancer drug
Posted July 11, 2012 5:13 pm.
This article is more than 5 years old.
TORONTO – Health Canada is warning that a contamination problem at a manufacturing plant in Toronto could affect global supplies of a bladder cancer drug.
The agency says it conducted an inspection which found mould in what is supposed to be a sterile manufacturing area of Sanofi Pasteur’s plant where the drug, ImmuCyst, is made.
Health Canada says it has concluded ImmuCyst should remain on the market, as long as it meets quality assurance standards.
Samples from each lot of the drug will be evaluated by both Sanofi and Health Canada before it can be shipped to market.
Health Canada says it has asked Sanofi to advise Canadian doctors of the situation and suggests patients who have concerns about the medication should speak with their health-care provider.
A spokesperson for Sanofi Pasteur was not immediately available for comment.
